

Direct comparison of the 0/1h- and 0/3h-algorithm for early rule-out of acute myocardial infarction

Patrick Badertscher, MD^{1,3#}; Jasper Boeddinghaus, MD^{1,2,3#}; et al.

[#]both authors contributed equally to and should be considered first author.

Short Title: Myocardial Infarction, Biomarkers, Diagnostic Testing, Guidelines

Running Title: Rule-out algorithms for AMI

Twitter: @CRIBasel, @BadertscherPat, @J_Boeddinghaus

Data sharing: The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure

Word count: 799

Correspondence to:

Prof. Dr. Christian Müller, CRIB and Department of Cardiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland

Phone Number: +41 61 328 65 49; Fax number: +41 61 265 53 53

E-mail: christian.mueller@usb.ch

2 Patients with symptoms suggestive of acute myocardial infarction (AMI) account for
3 about 10% of all emergency department (ED) presentations.(1) The majority of
4 patients are finally found to have diagnoses other than AMI.(2) Thus, the expeditious
5 evaluation of such patients is important as delays in ruling out AMI may interfere with
6 the detection of other underlying diseases. The 0/1hour(h)-algorithm and the 0/3h-
7 algorithm are both recommended by the European Society of Cardiology (ESC) with
8 a class I recommendation for the early rule-out of AMI.(1) The 0/1h- and the 0/3h-
9 algorithm are completely different protocols. While the 0/1h-algorithm uses high-
10 sensitivity cardiac troponin (hs-cTn) concentrations at presentation and absolute
11 changes within the first hour, and hence takes optimal advantage of the increased
12 diagnostic accuracy and precision of hs-cTn assays, the 0/3h-algorithm uses a fixed
13 threshold protocol based on the 99th percentile at presentation and 3h in conjunction
14 with clinical criteria (Global Registry of Acute Coronary Events (GRACE) score below
15 140 and the need to be pain-free). It is currently unknown whether one algorithm is
16 preferable to the other.

17 The aim of this study was to directly compare safety quantified by the negative
18 predictive value (NPV) and the negative likelihood ratio (LR) for the presence of AMI,
19 and efficacy quantified by the proportion of patients triaged towards rule-out in a
20 large diagnostic multicenter study enrolling patients presenting with suspected AMI to
21 the ED (NCT00470587). The study was carried out according to the principles of the
22 Declaration of Helsinki and approved by the local ethics committees. Written
23 informed consent was obtained from all patients. Patients presenting with ST-
24 Segment-Elevation MI were excluded. Triage towards rule-out by the 0/1h- or the
25 0/3h-algorithm was compared against the final adjudication performed by two
26 independent cardiologists using all information including cardiac imaging and serial

27 hs-cTnT measurements. Analyses were performed using hs-cTnT and hs-cTnI. NPV
28 and efficacy were compared using McNemar's test, respectively Pearson χ^2 test.
29 95%-Confidence intervals were calculated using the Wilson score method without
30 continuity correction.

31 Among 2547 patients eligible for analysis using hs-cTnT, AMI was the final
32 adjudicated diagnosis in 387 patients (15%). The 0/1h-algorithm provided similar
33 safety compared to the 0/3h-algorithm (NPV 99.8% (95%CI 99.4-99.9%) and
34 negative LR 0.01 (95%CI 0.00-0.03) versus 99.7% (95%CI 99.2-99.9%) and 0.02
35 (95%CI 0.00-0.05)), but allowed to rule-out significantly more patients as compared
36 to the 0/3h-algorithm (60% vs. 44%, $p<0.001$). Among 2197 patients eligible for
37 analysis using hs-cTnI, AMI was the final diagnosis in 327 patients (15%). The 0/1h-
38 algorithm provided higher safety compared to the 0/3h-algorithm (NPV 99.6%
39 (95%CI 99.1-99.9%) and negative LR 0.02 (95%CI 0.01-0.05) vs. 97.8% (95%CI
40 96.7-98.5%) and 0.13 (95%CI 0.09-0.19)), and allowed to rule-out a similar portion of
41 patients as compared to the 0/3h-algorithm (52% vs. 51%, $p=0.507$, Figure 1).

42 Overall, 711 patients (28%) presented within the first two hours from chest
43 pain onset (CPO). Safety for the 0/1h- and 0/3h-algorithm using hs-cTnT was very
44 high (NPV 99.6% (95%CI 98.4-99.9%) versus 100% (95%CI 98.9-100%) and
45 comparable to late presenters (CPO>2h) with 99.9% (95%CI 99.5-100%) versus
46 99.6% (95%CI 98.9-99.9%), respectively. The 0/1h-algorithm allowed to rule-out
47 more patients compared to the 0/3h-algorithm in early presenters (64% versus 49%
48 $p<0.001$) and in late presenters (59% versus 42%, $p<0.001$). Findings were
49 confirmed using hs-cTnI as well as using 30-days survival as an additional outcome
50 measure for safety with survival rates of 99.9%-100% for patients triaged towards
51 rule-out by both algorithms.

52 These findings corroborate and extend previous work on the development and
53 validation of safe and effective rule-out strategies for AMI and have important clinical
54 implications.(3–5) The excellent safety achieved with both algorithms documents the
55 suitability of most of these patients for early discharge and outpatient management.
56 Beyond the more favorable combination of safety and efficacy by the 0/1h-algorithm
57 versus the 0/3h-algorithm, the following features may help physicians and institutions
58 in the selection of their preferred triage algorithm. First, the 0/1h-algorithm has the
59 obvious and important additional advantage of allowing clinical decision-making two
60 hours earlier as compared to the 0/3h-algorithm. As most patients triaged towards
61 early rule-out are also candidates for direct discharge from the ED, it is very likely
62 that it will reduce time to discharge and treatment cost in the ED. Second, the 0/1h-
63 algorithm does not require the use of a specific risk score, which further increases its
64 feasibility. Previous studies have documented that omitting any of the three elements
65 of the 0/3h-algorithm (hs-cTn, GRACE-score, pain-free criteria) in an effort to simplify
66 the approach would worsen its safety and is therefore discouraged.(3) When putting
67 our findings into clinical perspective, it is important to highlight that the 0/1h-algorithm
68 and the 0/3h-algorithm should always be used in conjunction with all clinical
69 information available. This is of paramount importance as among patients presenting
70 with acute chest discomfort to the ED, the rule-out of AMI is related to the possibility
71 of rapid discharge and outpatient management, but not identical to it.

72 In conclusion, the 0/1h-algorithm is superior to the 0/3h-algorithm using hs-
73 cTnT as well as hs-cTnI, as it more favorably combines safety with efficacy.

74

75 **Author List**

Patrick Badertscher, MD^{1,3#}; Jasper Boeddinghaus, MD^{1,2,3#}; Raphael Twerenbold, MD^{1,3,4}; Thomas Nestelberger, MD^{1,3}; Karin Wildi, MD^{1,3}; Desiree Wussler, MD^{1,3}; Jonas Schwarz, MD^{1,3}; Christian Puelacher, MD^{1,3}; Maria Rubini Giménez, MD^{1,2,3}; Nikola Kozhuharov, MD^{1,3}; Jeanne du Fay de Lavallaz, MD^{1,3}; Sara Elisa Cerminara, MS¹; Eliska Potlukova, MD^{1,2}; Katharina Rentsch, PhD⁵; Òscar Miró, MD^{3,6}; Beatriz López, MD^{3,6}; F. Javier Martin-Sanchez, MD^{3,7}; Beata Morawiec, MD^{3,8}; Piotr Muzyk, MD⁸; Dagmar I. Keller, MD⁹; Tobias Reichlin, MD^{1,3}; and Christian Mueller, MD^{1,3}, for the APACE Investigators

#both authors contributed equally to and should be considered first author.

¹Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland; ²Department of Internal Medicine, University Hospital Basel, University Basel, Basel, Switzerland; ³GREAT network, Rome, Italy; ⁴Department of General and Interventional Cardiology, Hamburg University Heart Center, Hamburg, Germany; ⁵Laboratory Medicine, University Hospital Basel, University Basel, Basel, Switzerland; ⁶Emergency Department, Hospital Clinic, Barcelona, Catalonia, Spain; ⁷Servicio de Urgencias, Hospital Clínico San Carlos, Madrid, Spain; ⁸2nd Department of Cardiology, Medical University of Silesia, Zabrze, Poland; ⁹Emergency Department, University Hospital Zurich, Zurich, Switzerland.

76

77 **Funding**

The study was supported by research grants from the Swiss National Science Foundation, the European Union, the Swiss Heart Foundation, Abbott, Beckman Coulter, BRAHMS, Roche, Siemens, 8sense, Nanosphere, Alere and the Department of Internal Medicine, University Hospital Basel.

Conflict of interests

The authors designed the study, gathered and analyzed the data, vouched for the data and analysis, wrote the paper, and decided to publish. Drs. Badertscher, Boeddinghaus, and Mueller had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All

authors have read and approved the manuscript. The sponsors had no role in designing or conducting the study and no role in gathering or analyzing the data or writing the manuscript. The manuscript and its contents have not been published previously and are not being considered for publications elsewhere in whole or in part in any language, including publicly accessible web sites or e-print servers.

We disclose that Dr. Boeddinghaus received speaker honoraria from Siemens and research grants from the University of Basel and the Department of Internal Medicine. Dr. Twerenbold has received research support from the Swiss National Science Foundation (P300PB_167803), the University of Basel, the University Hospital of Basel and the Cardiovascular Research Foundation Basel as well as speaker honoraria/consulting honoraria from Roche, Abbott, Brahms, Siemens and Singulex. Dr. Rubini received speaker honoraria from Abbott and the research support from the Swiss Heart Foundation. Dr. Reichlin has received research grants from the Goldschmidt-Jacobson-Foundation, the Swiss National Science Foundation (PASMP3-136995), the Swiss Heart Foundation, the Professor Max Cloëtta Foundation, the Uniscientia Foundation Vaduz, the University of Basel and the Department of Internal Medicine, University Hospital Basel as well as speaker honoraria from Brahms and Roche. Dr. Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the Stiftung für kardiovaskuläre Forschung Basel; Abbott, Alere, Astra Zeneca, Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, Singulex, Sphingotec, and the Department of Internal Medicine, University Hospital Basel, as well as speaker honoraria/consulting honoraria from Abbott, Alere, Astra Zeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Cardiorientis, Novartis, Roche, Siemens, and Singulex.

All other authors declare that they have no conflict of interest with this study. The investigated hs-cTn assay were donated by the manufacturers, who had no role in the design of the study, the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication.

Appendix

78 **Additional APACE Investigators:**

79 Zaid Sabti, MD^{1,3}; Ivo Strebel, MSc¹; Samyut Shrestha, MD^{1,3}; Dayana Flores, MD^{1,3};
80 Michael Freese, RN^{1,3}; Claudia Stelzig, MSc¹; Caroline Kulangara, PhD¹; Kathrin
81 Meissner, RN¹; Nicolas Schaerli, MD^{1,2,3}; Deborah Mueller, MD^{1,3}; Ana Yufera
82 Sanchez, MD^{1,3}; Lorraine Sazgary, MD^{1,2,3}; Stella Marbot, MD^{1,3}; Carolina
83 Fuenzalida, MS^{3,4}; Sofia Calderón, MD^{3,4}; Esther Rodriguez Adrada, MD⁵; Damian
84 Kawecki, MD⁶; Ewa Nowalany-Kozielska, MD⁶; Jiri Parenica, MD^{3,7}; Eva Ganovská,
85 MD^{3,7}; Arnold von Eckardstein, MD⁸; Jens Lohrmann, MD^{1,10}; Wanda Kloos, MD^{1,10};
86 Stefan Osswald, MD¹; Andreas Buser, MD⁹; Roland Bingisser, MD¹⁰; Nicolas Geigy,
87 MD¹¹

88

89 ¹Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital
90 Basel, University of Basel; ²Department of Internal Medicine, University Hospital Basel, University of
91 Basel, both Switzerland; ³GREAT network; ⁴Emergency Department, Hospital Clinic, Barcelona,
92 Catalonia, Spain; ⁵Servicio de Urgencias, Hospital Clínico San Carlos, Madrid, Spain; ⁶2nd Department
93 of Cardiology, Medical University of Silesia, Zabrze, Poland; ⁷Department of Cardiology, University
94 Hospital Brno, Brno, Czech Republic and Medical Faculty, Masaryk University, Brno, Czech Republic;
95 ⁸Department of Laboratory Medicine, University Hospital Zurich, Zurich, Switzerland; ⁹Blood
96 Transfusion Centre, Swiss Red Cross, Basel, Switzerland and Department of Hematology, University
97 Hospital Basel, University Basel, Switzerland; ¹⁰Department of Emergency Medicine, University
98 Hospital Basel, University Basel, Switzerland; ¹¹Emergency Department, Kantonsspital Liestal,
99 Switzerland.

References

- 100
101 1. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ,
102 Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K,
103 Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S.
104 2015 ESC Guidelines for the management of acute coronary syndromes in
105 patients presenting without persistent ST-segment elevation. *Eur Heart J*.
106 2016;37:267–315.
- 107 2. Nestelberger T, Wildi K, Boeddinghaus J, Twerenbold R, Reichlin T, Giménez
108 MR, Puelacher C, Jaeger C, Grimm K, Sabti Z, Hillinger P, Kozhuharov N, du
109 Fay de Lavallaz J, Pinck F, Lopez B, Salgado E, Miró Ò, Bingisser R,
110 Lohrmann J, Osswald S, Mueller C. Characterization of the observe zone of
111 the ESC 2015 high-sensitivity cardiac troponin 0h/1h-algorithm for the early
112 diagnosis of acute myocardial infarction. *Int J Cardiol*. 2016;207:238–45.
- 113 3. Chapman AR, Anand A, Boeddinghaus J, Ferry A V., Sandeman D, Adamson
114 PD, Andrews J, Tan S, Cheng SF, D’Souza M, Orme K, Strachan FE,
115 Nestelberger T, Twerenbold R, Badertscher P, Reichlin T, Gray A, Shah ASV,
116 Mueller C, Newby DE, Mills NL. Comparison of the Efficacy and Safety of Early
117 Rule-Out Pathways for Acute Myocardial Infarction. *Circulation*.
118 2017;135:1586-1596.
- 119 4. Boeddinghaus J, Nestelberger T, Twerenbold R, Wildi K, Badertscher P, Cupa
120 J, Bürge T, Mächler P, Corbière S, Grimm K, Giménez MR, Puelacher C,
121 Shrestha S, Flores Widmer D, Fuhrmann J, Hillinger P, Sabti Z, Honegger U,
122 Schaerli N, Kozhuharov N, Rentsch K, Miró Ò, López B, Martin-Sanchez FJ,
123 Rodriguez-Adrada E, Morawiec B, Kawecki D, Ganovská E, Parenica J,
124 Lohrmann J, Kloos W, Buser A, Geigy N, Keller DI, Osswald S, Reichlin T,
125 Mueller C. Direct Comparison of 4 Very Early Rule-Out Strategies for Acute
126 Myocardial Infarction Using High-Sensitivity Cardiac Troponin I Clinical
127 Perspective. *Circulation*. 2017;135:1597-1611.
- 128 5. Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus
129 J, Nestelberger T, Sabti Z, Rubini-Giménez M, Puelacher C, Cupa J,
130 Schumacher L, Badertscher P, Grimm K, Kozhuharov N, Stelzig C, Freese M,
131 Rentsch K, Lohrmann J, Kloos W, Buser A, Reichlin T, Pickering JW, Than M,
132 Mueller C. Direct comparison of 2 rule-out strategies for acute myocardial
133 infarction: 2-h accelerated diagnostic protocol vs 2-h algorithm. *Clin Chem*.
134 2017;63:1227–36.
135

Figure 1 Direct comparison of the 0/1h- and 0/3h-algorithm for early rule-out of AMI using hs-cTnT (A) and hs-cTnI (B)

The figure is illustrating both co-primary endpoints: safety, as quantified by the negative predictive value (%), and efficacy (proportion of patients assigned to ruled-out, %). Bars represent 95% confidence intervals, hs-cTn = high sensitivity cardiac troponin. AMI = acute myocardial infarction.